Table 1.
Characteristics and medication of UC patients.
| Age | Disease duration (years) | Montreal Classification | Disease activity | Total Mayo Score | Endoscopic Mayo Score | WBC (x103/L) | CRP (mg/L) | Calprotectin (µg/g) | BMI (kg/m2) | Current IBD specific therapy |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 10 | E2 | Remission | 2 | 1 | 7.31 | 0.7 | 701 | 24.8 | mesalamine |
| 45 | 6 | E1 | Mild | 3 | 1 | 4.95 | 0.8 | <20 | na | mesalamine, AZA |
| 39 | 15 | E3 | Remission | 0 | 0 | 6.07 | 1.0 | 62 | 23.0 | vedolizumab |
| 41 | 5 | E2 | Mild | 4 | 2 | 6.27 | 1.4 | 647 | 28.4 | mesalamine, steroids |
| 66 | 32 | E3 | Remission | 0 | 0 | 8.12 | 1.5 | <20 | 24.8 | mesalamine |
| 68 | 4 | E2 | Moderate | 7 | 2 | 10.47 | 39.2 | 502 | 23.1 | mesalamine, steroids, antibiotics |
| 53 | 0.8 | E3 | Severe | 12 | 3 | 9.28 | 14.4 | 63 | 18.4 | mesalamine, steroids, tacrolimus |
| 48 | 11 | E3 | Remission | 2 | 2 | 6.65 | 1.5 | 781 | 30.3 | adalimumab |
| 57 | 14 | E2 | Remission | 2 | 0 | 6.66 | 3.5 | 218 | 19.7 | mesalamine |
| 39 | 2 | E3 | Moderate | 8 | 3 | 6.66 | 5.0 | 2162 | 24.7 | mesalamine |
| 29 | 13 | E2 | Remission | 2 | 1 | 8.76 | 1.3 | 272 | 15.5 | mesalamine, AZA, adalimumab |
| 63 | 13 | E2 | Mild | 4 | 1 | 4.61 | 4.4 | 126 | 26.2 | mesalamine, infliximab |
| 33 | 2 | E3 | Moderate | 9 | 3 | 16.99 | 73 | 2436 | 30.4 | mesalamine, golimumab, antibiotics, E. coli Nissle |
| 41 | 20 | E3 | Remission | 2 | 1 | 7.62 | 2.1 | <20 | 22.1 | AZA |
| 45 | 14 | E2 | Remission | 2 | 1 | 7.75 | 4.8 | 671 | 22.1 | mesalamine |
| 22 | 7 | E3 | Severe | 12 | 3 | 7.22 | 119.1 | 787 | 23.3 | AZA |
| 44 | nd | E3 | Moderate | 7 | 2 | 7.72 | 2.9 | na | 22.3 | none |
AZA, azathioprine; CRP, C-reactive protein; WBC, white blood cell count; BMI, body mass index; nd, newly diagnosed; na, not applied.